TY - JOUR
T1 - Coronavirus disease 2019 in patients with neuroendocrine neoplasms
T2 - Preliminary results of the INTENSIVE study
AU - Fazio, Nicola
AU - Gervaso, Lorenzo
AU - Halfdanarson, Thorvadur R.
AU - La Salvia, Anna
AU - Hofland, Johannes
AU - Hernando, Jorge
AU - Sonbol, Mohamad B.
AU - Garcia-Carbonero, Rocio
AU - Capdevila, Jaume
AU - de Herder, Wouter W.
AU - Koumarianou, Anna
AU - Kaltsas, Gregory
AU - Rossi, Maura
AU - Grozinsky-Glasberg, Simona
AU - Oleinikov, Kira
AU - Boselli, Sabrina
AU - Tamayo, Darina
AU - Bagnardi, Vincenzo
AU - Laffi, Alice
AU - Rubino, Manila
AU - Spada, Francesca
N1 - Funding Information:
The authors thank all the patients and their families. The authors thank all the researchers involved in this study. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/9
Y1 - 2021/9
N2 - Background: Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive. Material and methods: This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma. Results: Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31st, 2021, eight recruiting centres enrolled 89 patients. The median age was 64 years at the time of COVID-19 diagnosis. Most patients had metastatic, non-functioning, low-/intermediate-grade gastroenteropancreatic NENs on treatment with somatostatin analogues and radioligand therapy. Most of them had comorbidities. Only 8% of patients had high-grade NENs and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas most of them received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae, whereas 7.8% patients died due to COVID-19. Conclusions: Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.
AB - Background: Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive. Material and methods: This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma. Results: Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31st, 2021, eight recruiting centres enrolled 89 patients. The median age was 64 years at the time of COVID-19 diagnosis. Most patients had metastatic, non-functioning, low-/intermediate-grade gastroenteropancreatic NENs on treatment with somatostatin analogues and radioligand therapy. Most of them had comorbidities. Only 8% of patients had high-grade NENs and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas most of them received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae, whereas 7.8% patients died due to COVID-19. Conclusions: Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.
KW - Coronavirus
KW - COVID-19
KW - Neuroendocrine neoplasms
KW - Neuroendocrine tumours
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85110735476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110735476&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.06.029
DO - 10.1016/j.ejca.2021.06.029
M3 - Article
C2 - 34298375
AN - SCOPUS:85110735476
VL - 154
SP - 246
EP - 252
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -